MedTrace Logo

One Sequencing Find All for Helicobacter Pylori Infection

NCT03837990 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2019-05-14

No results posted yet for this study

Summary

The aim of this study is to Identify antibiotic resistance gene mutations in Helicobacter pylori (HP) and genetic diversity of drug metabolism for antibiotics and proton pump inhibitors (PPIs) in patients with HP infection using next-generation sequencing (NGS). The mutation of host/HP strain will be investigated by single NGS, and the eradication results according to genetic polymorphism of host/HP strain will be analyzed.

Conditions

  • Helicobacter Pylori Infection
  • Resistant Infection

Interventions

DRUG

Helicobacter Pylori eradication therapy

Eradication therapy includes the administration of a proton pump inhibitor (PPI) and antibiotics. Triple therapy with a PPI (lansoprazole or esomeprazole), clarithromycin, and amoxicillin is the first-line regimen. Quadruple therapy with a PPI, bismuth, metronidazole, and tetracyclin is the second-line therapy.

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Ju Han Kim, MD · Division of Biomedical Informatics,Seoul National University College of Medicine

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03837990 on ClinicalTrials.gov